| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | MENTIONED | LOW | Rob Black Show Stocks Fall As Yields Shoot Higher |
AstraZeneca was named among major IonQ partners that help establish the quantum company's credibility. [audio] | -0.7% | — | — |
| 2026-08-17 | MENTIONED | LOW | Rob Black Show Investors Weigh AI Optimism |
AstraZeneca strengthened two established oncology franchises while losing a first-line opportunity for an experimental immunotherapy, though Rob said late-stage oncology analysis is above him and he won't wade in. [audio] | +6.3% | +3.8% | — |
| 2026-08-03 | MENTIONED | MEDIUM | Rob Black Show Market Surges As Oil Prices Slide |
AstraZeneca is in talks to merge with Bristol Myers Squibb in a deal valued around $400 billion that would create the fourth-largest drugmaker by market cap. [audio] | +2.5% | +2.3% | — |
| 2026-07-20 | MENTIONED | LOW | Rob Black Show Afternoon podcast 7-20-26 |
AstraZeneca testing bi-specific antibodies for cancer drugs. [audio] | +3.1% | +0.3% | — |
| 2026-07-09 | SELL | MEDIUM | Rob Black Show Stocks Rose Supported By Jump In Semiconductors |
AstraZeneca is down 10% after its heart disease drug failed to meet targets; described as probably being oversold. [audio] | -5.2% | -9.6% | — |
| 2026-05-19 | MENTIONED | LOW | Rob Black Show Stocks Slide Under Pressure From Higher Rates |
AstraZeneca is listed as one of the pharmaceutical companies offering discounts on TrumpRx. [audio] | +1.4% | -5.3% | -15.0% |